clinical trial · NCT07450664
Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome
Soleno Therapeutics, Inc.·—·enrolling by invitation·n = 200
Prader-Willi SyndromeVYKAT XR
brief summary
Prospective observational study developed to generate more evidence of the safety profile, clinical characteristics and outcomes of patients with PWS treated with VYKAT XR.
started
Nov 26, 2025
primary completion
Mar 1, 2028
completion
Mar 2, 2028
last updated
Apr 16, 2026
detailed description
Patients with PWS at participating sites who are initiating treatment or have initiated treatment with VYKAT XR, including patients who were previously treated with DCCR in a prior clinical study, will be invited to participate. Data from treatment prior to enrollment either from clinical practice or from previous DCCR clinical trials may be collected retrospectively.
Clinical care will not be mandated by the protocol.
official title
An Observational Study of VYKAT™ XR (Diazoxide Choline Extended-Release Tablets) in Patients With Prader-Willi Syndrome (PWS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol